Advertisement
Organisation › Details
Oryzon Genomics (Group)
Founded in 2000 in Barcelona, Spain, Oryzon (ISIN Code: ES0167733015) is a clinical stage biopharmaceutical company considered as the European champion in Epigenetics. The company has one of the strongest portfolios in the field and a clinical asset already partnered with Roche. Oryzon’s LSD1 program is currently covered by + 20 patent families and has rendered two compounds in clinical trials. In addition, Oryzon has ongoing programs for developing inhibitors against other epigenetic targets. The company has a strong technological platform for biomarker identification and performs biomarker and target validation for a variety of malignant and neurodegenerative diseases. Oryzon’s strategy is to develop first in class compounds against novel epigenetic targets through Phase II clinical trials, at which point it is decided on a case-by-case basis to either keep the development in-house or to partner or outlicense the compound for late stage development and commercialization. The company has offices in Barcelona and Cambridge, Massachusetts. *
Start | 2000-06-02 established | |
Industry | LSD1 inhibitor (Lysine Specific Demethylase-1 inhibitor) | |
Industry 2 | ORY-1001 (RG6016) (Oryzon/Roche) | |
Person | Buesa, Carlos (Oryzon Genomics SA 201404 CEO + Co-Founder) | |
Person 2 | Rello, Enric (Oryzon Genomics 201605 CFO) | |
Region | Madrid | |
Country | Spain (España) | |
Street | 15 Carrera de San Jerónimo 2nd Floor | |
City | Madrid | |
Address record changed: 2020-12-02 | ||
Basic data | Employees | n. a. |
* Document for »About Section«: Oryzon Genomics S.A.. (5/16/17). "Press Release: Oryzon Announces Appointment of New Chief Medical Officer and Expansion of Its Medical Department". Barcelona & Cambridge, MA. | ||
Record changed: 2023-07-10 |
Advertisement
More documents for Oryzon Genomics (Group)
- [1] Oryzon Genomics S.A.. (10/26/18). "Press Release: Oryzon Raises EUR 13 Million through a Private Placement with US and European Investors [Not for US, CA, AU, JP, ZA or any other jurisdiction where unlawful]". Madrid & Cambridge, MA....
- [2] Oryzon Genomics S.A.. (10/22/18). "Press Release: Oryzon to Present at Upcoming International Conferences". Madrid & Cambridge, MA....
- [3] Oryzon Genomics S.A.. (5/14/18). "Press Release: Oryzon Announces First Patients In ETHERAL – a Phase IIa Clinical Trial in Alzheimer’s Disease with ORY-2001". Madrid & Cambridge, MA....
- [4] Oryzon Genomics S.A.. (10/3/17). "Press Release: Significant Fact [Company Moves Registered Address from Barcelona to Madrid]". Madrid....
- [5] Oryzon Genomics S.A.. (7/20/17). "Press Release: Oryzon to Regain Rights to ORY-1001 (RG6016)". Barcelona & Cambridge, MA....
- [6] Oryzon Genomics S.A.. (5/31/17). "Press Release: Oryzon Genomics to Participate in a Panel at the JMP Securities Life Sciences Conference and Present at the Jefferies 2017 Global Health Conference". Barcelona & Cambridge, MA....
- [7] Oryzon Genomics S.A.. (5/16/17). "Press Release: Oryzon Announces Appointment of New Chief Medical Officer and Expansion of Its Medical Department". Barcelona & Cambridge, MA....
- [8] Oryzon Genomics S.A.. (3/31/17). "Press Release: Oryzon Raises €18 Million through a Private Placement with US and European Investors [Not for US, CA, AU, JP, ZA, et al.]". Barcelona....
- [9] Oryzon Genomics S.A.. (2/27/17). "Press Release: Oryzon Presented New Preclinical Data of ORY-2001 Therapeutic Activity in Multiple Sclerosis at ACTRIMS-2017". Barcelona & Cambridge, MA....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top